BRIEF-Cmg Announces The Acquisition Of Sharp Reflections GmbH-February 2024-www.financetom.com

BRIEF-Cmg Announces The Acquisition Of Sharp Reflections GmbH

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Cmg Announces The Acquisition Of Sharp Reflections GmbH

Nov 12, 2024 9:55 PM

Nov 12 (Reuters) - Computer Modelling Group Ltd ( CMDXF )

* CMG ANNOUNCES THE ACQUISITION OF SHARP REFLECTIONS GMBH

* COMPUTER MODELLING GROUP LTD ( CMDXF ) - PAYS €25 MILLION ($37

MILLION)

FOR SHARP REFLECTIONS

* COMPUTER MODELLING GROUP LTD ( CMDXF ) - BILL SHEA TO REMAIN AS CEO

SHARP REFLECTIONS

Source text:

Further company coverage:

Previous page： GEO Group Unveils $70 Million CapEx to Expand Services; Plans to Reduce Debt Next page： Merck Discontinues Vibostolimab, Favezelimab Clinical Trials

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

GEO Group Unveils $70 Million CapEx to Expand Services; Plans to Reduce Debt

Dec 16, 2024

05:13 PM EST, 12/16/2024 (MT Newswires) -- GEO Group ( GEO ) said late Monday it plans to invest $70 million to strengthen its capabilities to deliver expanded detention capacity, secure transportation, and electronic monitoring services to US Immigration and Customs Enforcement. The company said it intends to pursue a possible sale of underperforming company-owned state correctional facilities to offset...

Merck Discontinues Vibostolimab, Favezelimab Clinical Trials

Dec 16, 2024

05:13 PM EST, 12/16/2024 (MT Newswires) -- Merck ( MRK ) said Monday it is discontinuing the clinical development programs for vibostolimab and favezelimab. Merck ( MRK ) said it is ending Phase 3 trials in the KeyVibe program, which assesses the fixed-dose combination of vibostolimab and pembrolizumab in certain patients with non-small cell lung cancer, based on the recommendation...

Central Garden & Pet Increases Share Buyback Plan

Dec 16, 2024

05:13 PM EST, 12/16/2024 (MT Newswires) -- Central Garden & Pet ( CENT ) said Monday its board has approved a $100 million increase in its authorization to repurchase shares, bringing total repurchase authorization to about $130 million. The share repurchase program does not have an expiration date, the firm said. ...

Enghouse Acquires AI Software Company Aculab PLC

Dec 16, 2024

05:13 PM EST, 12/16/2024 (MT Newswires) -- Enghouse Systems ( EGHSF ) , after trading Monday said its U.K. unit acquired Aculab PLC, a provider of on-premise and cloud based communications and AI software, for an undisclosed price. Aculab products include a communications platform as a service (CPaaS), an AI-driven answering machine detection, advanced voice and face biometrics technologies, as...